Evofem Q1 net loss $5.5M ($0.04/sh) vs prior net income; sales rise to $0.9M

Evofem Biosciences, Inc.

2026-Q1 EPS reported -$0.04 revenue$899,000

Net loss $5.5M ($0.04 per share) vs net income $1.0M ($0.01 per share) in Q1 2025.
Net sales $0.9M, up ~12.5% from $0.8M in Q1 2025; driven by higher WAC and improved gross-to-net.
Operating expenses $5.5M after excluding a one-time $5.6M R&D reduction from trade payables settlement.
Entered distribution agreement for SOLOSEC in Sub-Saharan Africa with Clovis Davis Pharmaceuticals.
UAE regulatory review ongoing; pricing certificates for PHEXX obtained; NIH-funded Phase 4 trial enrolling patients.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.